Efficacy and tolerability of adjunctive modafinil /armodafinil in bipolar depression: a meta-analysis of randomized controlled trials.
The aim of this study was to evaluate the efficacy and safety of the dopaminergic enhancing agent modafinil/armodafinil (MoArm) as adjunctive treatment for bipolar depression. A comprehensive search of major electronic databases was conducted to identify randomized controlled trials (RCTs) of adjunctive MoArm that included patients with bipolar I (BPI) or bipolar II (BPII) depression. Data for response/remission and all-cause discontinuation were analyzed. Effect size was summarized by relative risk (RR) using a random effect model. Of 58 studies, Five RCTs (N=795 drug, N=792 placebo) met inclusion criteria. Four armodafinil studies included only BPI patients and one modafinil study included both bipolar subtypes with limited heterogeneity (I2 = 34%, P = 0.19; I2 = 18%, P = 0.30). Compared to placebo, augmentation with MoArm was associated with significantly greater rates of treatment response (RR, 1.18; 95% CI, 1.01-1.37; p=0.03) and remission (RR, 1.38; 95% CI, 1.10-1.73; p=0.005). All cause discontinuation was no different than placebo (RR, 1.08; 95% CI, 0.89-1.30, p=0.45) with no evidence of increased risk of mood switch or suicide attempts with MoArm (RR, 0.99; 95% CI, 0.39-2.5, p=0.98; RR, 1.02; 95% CI, 0.37-2.85, p=0.97). This narrower scope meta-analysis of one drug for one disease suggests that adjunctive modafinil / armodafinil may represent a novel therapeutic intervention. Further studies delineating subtypes of bipolar depression responsive to these novel dopaminergic enhancing agents are encouraged.